Philips Unveils Next-Generation CT and MR Platforms to Advance Precision in Radiation Oncology
At the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Royal Philips introduced a suite of new imaging technologies designed to improve precision, efficiency, and patient experience in radiation therapy planning. The company highlighted its latest CT simulation platforms—Philips Rembra RT and Areta RT—alongside the new helium-free BlueSeal RT 1.5T MR system. Together, these innovations reflect a push to help oncology teams manage increasingly complex treatment planning while navigating workforce and resource constraints.
CT simulation remains the cornerstone of radiation therapy planning, but as expectations for accuracy and speed continue to rise, the demand for more advanced tools is intensifying. Philips’ Rembra RT and Areta RT platforms are engineered to deliver clearer images with improved consistency, enabling oncologists to visualize tumors in greater detail. Faster image reconstruction—up to 106 images per second—streamlines workflows, while intuitive touchscreen gantry controls were shown to improve efficiency for more than 90% of care teams. The systems also feature an 85 cm extended field of view and next-generation 4DCT, capable of capturing a full respiratory cycle across a broad range of breathing patterns.
For patients, the technology translates into faster examinations, shorter waiting times, and more flexible positioning on high-performance treatment tables. For hospitals, Philips has added long-term reliability with its Tube for Life Guarantee and system design built for up to two decades of service, reducing lifetime ownership costs. Importantly, the CT simulators also support remote collaboration for training and treatment planning—an increasingly valuable feature as departments adapt to staffing shortages.
“Philips invented CT simulation and introduced the first Big Bore RT system,” said Dan Xu, Business Leader of CT at Philips. “With Rembra RT and Areta RT, we are once again setting new standards for radiation therapy, empowering care teams with precision, dependability, and speed.” The company is also collaborating with MVision AI to integrate Contour+, an AI-powered auto-segmentation tool that automatically delineates organs at risk and lymph node areas, further enhancing efficiency and reproducibility in treatment planning.
Alongside its CT innovations, Philips also announced the introduction of BlueSeal RT, a helium-free 1.5T MR scanner designed specifically for radiation oncology. MR imaging is playing a growing role in guiding radiation therapy by providing detailed visualization of tumors and adjacent healthy tissue. BlueSeal RT, powered by AI-driven SmartSpeed Precise software, enhances simulation accuracy while reducing registration errors. The system also supports MR-only workflows, with protocols completed in as little as 10 minutes, improving patient comfort during simulation sessions.
With more than 2,000 helium-free MR scanners already installed worldwide, Philips has been at the forefront of sustainable imaging. BlueSeal RT brings that approach into radiation oncology, with a vent-pipe-free, lightweight design that allows installation in challenging environments such as basements, bunkers, or higher floors. It also reduces operating costs and environmental impact through helium-free operation and PowerSave+ efficiency.
“BlueSeal RT is leading the way in MR for radiotherapy,” said Ioannis Panagiotelis, PhD, Business Leader MR at Philips. “By combining sustainability with AI-powered acceleration, we are enabling oncology teams to plan treatments with greater speed and accuracy, while improving the patient experience.”
Clinicians echoed the significance of these launches. “Radiation oncology teams need transformative innovation to meet today’s accuracy, workflow, and cost challenges,” said Christopher M. Freese, MD, of The Christ Hospital. “With Rembra RT, Areta RT, and BlueSeal RT, Philips is setting new benchmarks for precision and efficiency across CT and MR.”